Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Syridex Bio is a venture capital firm founded in 2022 by Squire Servance, based in Princeton, New Jersey. The firm is dedicated to building companies that address inequities in health innovation, particularly for underserved communities. Syridex Bio combines venture creation and private equity strategies to focus on therapies for diseases disproportionately affecting ethnic minorities, LGBTQ+ communities, and rural populations.
The firm has been selected by the New Jersey Economic Development Authority (NJEDA) to invest up to $5 million in early-stage life science companies within New Jersey. This allocation highlights Syridex's commitment to supporting local innovation and improving health outcomes through targeted investments.
Currently, Syridex Bio operates with a dual strategy: venture creation, which involves building companies around acquired pharmaceutical and biotech products, and private equity, which focuses on privatizing undervalued public pharma and biotech companies. This approach allows Syridex to create agile, well-capitalized companies that can effectively address pressing health challenges.
Syridex Bio invests in life sciences companies that develop innovative solutions for diseases affecting underserved populations. Their investment strategy encompasses several key sectors, including biotech, healthcare, and digital health. The firm primarily targets Seed and Series A stages, focusing on North American companies.
The firm emphasizes rigorous diligence to validate opportunities in emerging fields of science and medicine. Syridex Bio aims to ensure that health innovation is accessible and equitable, particularly for communities that have historically faced barriers to healthcare. Their investment thesis revolves around creating sustainable ventures that improve health outcomes for underserved populations.
Additionally, Syridex Bio's private equity arm seeks to acquire undervalued public pharma and biotech companies, allowing them to take these entities private and enhance their operational capabilities. This dual approach enables Syridex to build a diverse portfolio of companies that align with their mission of health equity.
Syridex Bio's portfolio includes two notable companies:
Both companies exemplify Syridex Bio's commitment to addressing health inequities through innovative solutions in the life sciences sector.
Squire Servance - Founder & Managing Partner. Squire has a background in life sciences investing and operations, with a focus on building companies that address health inequities.
Veleka Peeples-Dyer - Partner. Veleka brings expertise in healthcare investments and has a strong track record in supporting early-stage companies.
Joshua Adeoye, MD - Principal. Joshua has a medical background and specializes in identifying innovative healthcare solutions that can improve patient outcomes.
Christopher Whitfield - Advisory Partner. Christopher provides strategic guidance and industry insights, leveraging his extensive experience in the life sciences sector.
To pitch Syridex Bio, founders should send an email to info@syridexbio.com. It is recommended to include a comprehensive pitch deck that outlines the problem being addressed, the proposed solution, market analysis, and team qualifications.
While there is no formal application portal, a well-structured email pitch is preferred. Founders can expect a response within a few weeks, depending on the volume of inquiries. Warm introductions are beneficial but not mandatory.
In 2023, Syridex Bio was selected by the New Jersey Economic Development Authority (NJEDA) to invest up to $5 million in early-stage life science companies in New Jersey. This announcement was made via BusinessWire and highlights the firm's commitment to supporting local innovation.
Additionally, Syridex Bio has been featured in various publications, including DiversityQ, NJBIZ, and Innovations of the World, focusing on their mission to promote health equity through commercial life sciences investing.
What are Syridex Bio's investment criteria?
Syridex Bio focuses on life sciences companies that develop solutions for diseases disproportionately affecting underserved populations. They invest primarily in Seed and Series A stages, targeting biotech, healthcare, and digital health sectors.
How can I pitch Syridex Bio?
Founders can reach out via email at info@syridexbio.com. It is advisable to include a detailed pitch deck that outlines the problem, solution, market opportunity, and team background.
What makes Syridex Bio different from other investors?
Syridex Bio combines venture creation with private equity strategies, focusing on health equity and social impact. Their unique approach includes building companies around acquired assets and targeting undervalued public companies for privatization.
What is Syridex Bio's geographic focus?
The firm primarily invests in North America, with a specific emphasis on early-stage life science companies in New Jersey, supported by their partnership with the NJEDA.
What kind of support do portfolio companies receive?
Syridex Bio provides operational support, strategic guidance, and access to a network of industry experts to help portfolio companies succeed. They are actively involved in the growth and development of their investments.
What is the typical check size for investments?
While specific check sizes are not disclosed, Syridex Bio has the capacity to invest up to $5 million in early-stage companies, particularly those located in New Jersey.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.